INCB054828 (pemigatinib), a potent and selective inhibitor of fibroblast growth factor receptors 1, 2, and 3, displays activity against genetically defined tumor models

Alterations in fibroblast growth factor receptor (FGFR) genes have been identified as potential driver oncogenes. Pharmacological targeting of FGFRs may therefore provide therapeutic benefit to selected cancer patients, and proof-of-concept has been established in early clinical trials of FGFR inhib...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Phillip C. C., Koblish, Holly, Wu, Liangxing, Bowman, Kevin, Diamond, Sharon, DiMatteo, Darlise, Zhang, Yue, Hansbury, Michael, Rupar, Mark, Wen, Xiaoming, Collier, Paul, Feldman, Patricia, Klabe, Ronald, Burke, Krista A., Soloviev, Maxim, Gardiner, Christine, He, Xin, Volgina, Alla, Covington, Maryanne, Ruggeri, Bruce, Wynn, Richard, Burn, Timothy C., Scherle, Peggy, Yeleswaram, Swamy, Yao, Wenqing, Huber, Reid, Hollis, Gregory
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7313537/
https://www.ncbi.nlm.nih.gov/pubmed/32315352
http://dx.doi.org/10.1371/journal.pone.0231877

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7313537/
https://www.ncbi.nlm.nih.gov/pubmed/32315352
http://dx.doi.org/10.1371/journal.pone.0231877

Ejemplares similares